Pharmaceutical Development Services Ltd. (PDS) has opened an office in South Carolina to support expansion efforts in the U.S. Dr. Jeff Rudolph will guide U.S. pharmaceutical companies with drug development in Europe, covering regulation, quality management, European legal framework and the sourcing of local contractors.
Dr. Michael Gamlen, managing director of PDS, said, "Having established expert knowledge in European pharmaceutical development, we have built up a bank of expertise in our team that can considerably shorten the timescales and reduce the costs for American companies of introducing pharmaceutical products into Europe. Our business from U.S. companies has steadily increased and by opening a U.S. office with Dr. Rudolph as our main contact point, we are ensuring that we can effectively manage our expansion in the U.S."
Dr. Rudolph is an experienced pharmaceutical scientist with more than 30 years of experience with domestic and international development and management of branded, generic and OTC products. He held senior pharmaceutical development positions at McNeil Laboratories (J&J) and spent 23 years at AstraZeneca and its predecessor companies, where his responsibilities included vice president, international pharmaceutical development/R&D operations. Dr. Rudolph most recently provided consulting services to the healthcare industry in the areas of CMC, process optimization, production troubleshooting, device design, organizational and business development as well as serving as an expert witness on formulation/drug delivery patent cases.
Magazine
